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Abstract
The prevalence of obesity worldwide has dramatically
increased during the last three decades. With obesity
comes a variety of adverse health outcomes which
are grouped under the umbrella of metabolic
syndrome. The liver in particular seems to be
significantly impacted by fat deposition in the
presence of obesity. In this article we discuss several
liver conditions which are directly affected by
overweight and obese status, including non-alcoholic
fatty liver disease, chronic infection with hepatitis C
virus and post-liver transplant status. The deleterious
effects of obesity on liver disease and overall health
can be significantly impacted by a culture that fosters
sustained nutritional improvement and regular
physical activity. Here we summarize the current
evidence supporting non-pharmacological, lifestyle
interventions that lead to weight reduction, improved
physical activity and better nutrition as part of the
management and treatment of these liver conditions.
Introduction
Severe liver disease has significant effects on an indivi-
dual’s quality of life (QOL) as well as their life expec-
tancy. The treatment of many of these conditions
involves multi-drug regimens which can be associated
with a variety of side effects. Although therapy with pre-
scription medication is often unavoidable, maximizing
lifestyle interventions can play a key role in maintenance
of overall health augmenting medical therapy in patients
with chronic liver disease. Recently published studies
have advanced our understanding of how various life-
style interventions may improve the pathology and
symptoms related to specific liver diseases, thereby
improving quality of life for these patients.
Lifestyle modifications are strongly recommended for
patients with non-alcoholic fatty liver disease (NAFLD),
h e p a t i t i sCv i r u s( H C V ) ,a sw e l la sp a t i e n t sw h oh a v e
undergone liver transplantation. Even when efficacious
pharmacologic interventions are identified, lifestyle
changes will likely represent an adjuvant treatment
because new drugs are inevitably expensive and may
have unanticipated adverse effects after prolonged use.
These lifestyle modifications typically encompass both
dietary intervention and physical activity goals. Unfortu-
nately, these straightforward goals are surprisingly hard
to achieve in an environment of copious amounts of
high-calorie food and busy daily routines that seem to
preclude time for exercise. Many of these difficulties can
only be overcome by a culture change that values
wholesome foods and regular exercise over the conveni-
ence of prepared foods and sedentary activities. In the
following sections we will discuss the current evidence
for non-pharmacological, lifestyle interventions in the
management of some of the most common causes of
chronic liver disease including NAFLD, chronic HCV
infection, as well as in the liver transplant population.
Non-alcoholic fatty liver disease
It has been well documented in the medical literature
that several types of hepatic conditions are dependent
upon or worsened by the presence of obesity in patients.
It has become clear that obesity and features of the
metabolic syndrome, which encompass glucose dysregu-
lation, dyslipidemia and hypertension, are key risk fac-
tors for the development and progression of NAFLD [1].
The presentation and severity of NAFLD can vary signif-
icantly, from simple steatosis (which represents fatty
deposition without inflammation) to non-alcoholic stea-
tohepatitis or NASH (which encompasses steatosis,
inflammation and ballooning degeneration of hepato-
cytes) to liver fibrosis and end-stage liver disease. Due
to increasing rates over the last few decades, NAFLD
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chronic liver disease in most of the Western World,
with a prevalence ranging from 20 to 35% of adults and
5 to 17% in children [2,3]. NAFLD has a close associa-
tion with disordered insulin utilization in the body, thus
patients with NAFLD often suffer from insulin resis-
tance and Type II diabetes. Multiple studies have been
performed detailing the relationship between insulin
resistance and NAFLD and have shown that disordered
insulin regulation results in multiple, altered metabolic
pathways which ultimately lead to fat deposition and
inflammation in the liver [4,5]. Patients diagnosed with
metabolic syndrome are at high risk for developing car-
diovascular disease including myocardial infarction and
stroke. Further, a growing body of evidence suggests
t h a tt h ep r e s e n c eo fN A F L Di sar i s kf a c t o rf o rc a r d i o -
vascular disease independent of the presence of other
features of metabolic syndrome [6,7]. Given the fact that
these patients are at risk of both severe liver damage
and cardiovascular disease, efforts at weight loss and
lifestyle changes are paramount in their overall care. In
addition, although there is intense research to identify
effective medications for this condition, there is cur-
r e n t l yn oc o n s e n s u sf o rt h eu s eo fa n ys i n g l ed r u go r
drug combination for treatment of NAFLD.
Over the last few years there have been several studies
published which have attempted to determine the effects
of either diet and/or exercise on NAFLD; however,
most of these studies have been limited due to the
small number of patients studied, the short duration of
intervention, and the lack of control arms. Table 1
summarizes the main features of these studies. Uneo
and colleagues were one of the first groups to report
on the effects of diet and exercise on NAFLD. They
demonstrated that a short-term, restricted diet and exer-
cise program lasting three months led to a decrease in
liver enzymes, improved cholesterol and blood glucose
levels in patients with NAFLD [8]. In their cohort of
patients who completed the diet and exercise program,
body mass index (BMI) decreased from 31 kg/m
2 to
28 kg/m
2, while the control group gained weight. More
recently, St. George et al. examined the impact of a
behavior change-based lifestyle intervention on physical
activity levels and the effects of these changes on the
metabolic profile of patients with fatty liver disease [9]
They reported that enhanced physical activity alone
favorably impacted patients with NAFLD including
reduction in both aminotransferase levels and other
metabolic indices. Notably, the effects of these changes
were independent of weight loss. Both of these studies
imply that lifestyle modification in the short-term (three
months duration for each study) is successful in improv-
ing not only the effects of NAFLD, but also other
features of the metabolic syndrome for these patients. In
addition, a 2009 study evaluated the effects of four
weeks of an aerobic exercise program on NAFLD and
obesity utilizing MRI findings related to NAFLD before
and after the exercise intervention. The authors reported
a mean reduction of hepatic triglyceride content by 21%
as well as a reduction of visceral adipose tissue volume
by 12% for patients who participated in the exercise
program [10]. Importantly, these changes were in the
Table 1 Clinical studies evaluating outcome of lifestyle interventions for obese adults and children with NAFLD
Author Patients
(n)
Study type Therapy Duration Outcome
Franzese et al. [38] 58 Case series Diet and
exercise
Six
months
85% of patients with NAFLD (19/33) with normalization or
improvement in US findings of NAFLD
Huang et al. [11] 23 Pilot study Diet one year NASH improved In 60% of patients
Johnson, NA [10] 19 Randomized,
controlled trial
Exercise four
weeks
Reduction of hepatic triglyceride concentration, visceral adipose tissue
volume and hepatic free fatty acids
Nobili V et al. [16] 53 Randomized,
controlled trial
Diet and
exercise
24
months
Children experienced weight loss and improved liver histology after
lifestyle intervention
Oza et al. [39] 22 Pilot study Diet six
months
BMI and steatosis reduced in 86% of patients who completed the
study (only 32% of patients completed the study)
Palmer et al. [40] 39 Case series Diet and
exercise
2 to 111
months
Liver enzymes improved in patients with weight loss
Promrat et al. [37] 31 Randomized,
controlled trial
Diet and
exercise
48 weeks More patients with lifestyle intervention had reduction in NAS score in
comparison with control group
St. George et al.
[9]
152 Randomized trial Diet and
exercise
three
months
Reduction of liver enzymes in both the low-intensity and moderate-
intensity groups
Ueno et al. [8] 25 Non-randomized,
controlled trial
Diet and
exercise
three
months
Steatosis improved in the intervention group
Viljanen et al. [12] 34 Case Series Diet six weeks Decreased liver volume and liver fat content, improved hepatic insulin
resistance
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in the reversal of hepatic lipid accumulation. Examining
the effects of diet alone in patients with NAFLD, Huang
et al. reported that after one year of intense nutritional
therapy, 60% of patients experienced histologic improve-
ment of NAFLD according to Brunt’s criteria; however,
only 70% of patients (16 out of 23) enrolled successfully
completed the one year program [11]. Given the inti-
mate relationship between insulin resistance and
NAFLD, studies have also examined hepatic insulin
resistance in the face of lifestyle changes. After six
weeks of maintaining a low calorie diet, 33 obese sub-
jects experienced a 32% increase in whole-body insulin
sensitivity and 60% decrease in hepatic insulin resistance
on average [12]. The patients also experienced an 11%
reduction in liver volume, 60% decrease in liver trigly-
ceride content as determined by magnetic resonance
studies. It has become evident in the literature that
interventions which result in definite weight loss can
lead to significant improvements in NAFLD. Nowhere is
this more evident than in the bariatric surgery popula-
tion. Several studies have shown that bariatric surgery
results in marked improvement of liver histopathological
features such as steatosis, inflammation, and hepatocyte
ballooning as well as serum liver enzymes and measure-
ments of insulin resistance in patients with severe
obesity and NAFLD [13,14].
NAFLD is also being identified more frequently in the
pediatric population. These children also tend to be
overweight, with a BMI above the 85% for age, or obese
with a BMI above the 95% for age. Many parents of
young patients with NAFLD prefer to avoid medications
in favor of lifestyle modifications. Parents and physicians
alike are concerned about the endpoint of medication
use and potential long-term side effects of medications
when started at such a young age. Thus, many parents
and providers seek out programs that address lifestyle
modification for obese children with metabolic compli-
cations of obesity including NAFLD. Currently available,
non-invasive diagnostic tests are unable to reliably pre-
dict which patients will progress from hepatic steatosis
to advanced liver disease and fibrosis; therefore, it has
been suggested that diet and exercise should be the
first-line of defense for preventing progression to wor-
sening states of liver damage [15]. Evidence for this has
come from a study of 53 children with NAFLD under-
going lifestyle modifications including behavioral, dietary
and physical activity recommendations. It was reported
that these children experienced significant improvement
in BMI, NAFLD Activity Score (NAS), hepatic lobular
inflammation, hepatocyte ballooning and transaminases
during the 24-month study period [16]. Additionally,
the patients also showed improvement in choleste-
rol, triglycerides and HOMA-IR (homeostasis model
assessment-insulin resistance), a sensitive indicator of
insulin resistance.
Each of the aforementioned studies did document
improved hepatic steatosis and/or improvement in liver
enzymes after lifestyle modification, but multiple clinical
challenges still remain. More research is needed to
determine the optimal length of time required for these
types of interventions. In addition, compliance with
these types of programs can be an issue for patients.
Proven methods to maintain patient interest, attendance
and adherence are needed as well.
Chronic hepatitis C virus (HCV) infection
Hepatitis C virus (HCV) infection continues to be an
important global health problem. It is estimated that
approximately 170 million people worldwide are infected
w i t hH C V[ 1 7 ] .W h i l ean u m b e ro fh o s ta n dv i r a l
related factors are well established predictors of
response to anti-viral therapy and clinical outcome, obe-
sity and the associated metabolic complications have
been increasingly recognized as independent risk factors
for diminished response to therapy and more severe
liver disease. Indeed, an elevated body mass index is
associated with increased ste a t o s i si np a t i e n t sw i t h
chronic HCV. This association appears to be present
irrespective of HCV genotype [18]. In turn, increasing
severity of hepatic steatosis has been associated with dis-
ease progression, worsening liver damage and fibrosis in
patients with chronic HCV [19]. Although the exact
mechanisms for disease progression in patients with
steatosis have not been completely elucidated, it has
been shown that obese patients with chronic HCV have
higher circulating insulin levels, which are associated
with higher levels of fibrosis [18]. A recent study of 228
patients with chronic HCV infection reported that 26%
of the patients fulfilled criteria for metabolic syndrome.
The diagnosis of metabolic syndrome was significantly
associated with both genotype 1 HCV as well as steato-
sis of the liver [20]. Additionally, in a study evaluating
more than 900 patients with advanced chronic HCV
resistance to standard therapy, approximately 25% had
both diabetes and elevated serum triglycerides. Several
additional studies have also assessed the prevalence of
Type 2 diabetes mellitus in patients with chronic hepati-
tis C infection, affecting between 8 and 25% of these
patients [21,22]. Insulin resistance, as determined by
HOMA-IR, and histological features of fatty liver,
including degree of steatosis and presence of Mallory
bodies, was associated with progressive liver disease in
this cohort of patients [23]. There is evidence that the
development of insulin resistance might be linked
directly to the hepatitis C virus itself. Romero-Gomez
et al. found that in 50 patients with chronic hepatitis C
and a diagnosis of insulin resistance before anti-viral
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also experienced a decrease in HOMA-IR six months
after therapy was initiated in comparison to patients
who were non-responders [24].
In addition to the association with progression of liver
disease, there have also been studies investigating altera-
tions in response to standard medical therapy for
patients with chronic hepatitis C, obesity and hepatic
steatosis. It has become clear that increased body weight
has a detrimental effect on the sustained virological
response to antiviral therapy in chronic HCV [25]. In
fact, Hanouneh et al. reported that patients with chronic
hepatitis C infection as well as metabolic syndrome were
3.8 times more likely to fail standard anti-viral treatment
with pegylated interferon (alpha-2b or alpha-2a) and
ribavirin than patients without metabolic syndrome [20].
It has also been shown that in patients with chronic
hepatitis C, insulin resistance (as indicated by increased
HOMA-IR) is an independent predictor of decreased
viral response to standard therapy [24].
A logical approach to addressing patients with meta-
bolic syndrome and chronic hepatitis C would be to
treat the underlying liver disease and relevant compo-
nents of metabolic syndrome simultaneously. Examining
lifestyle interventions as a means for treating metabolic
syndrome in these patients, a study of 31 obese patients
with chronic hepatitis C, steatosis and overweight status
who underwent 15 months of physical activity and diet-
ary intervention showed that 68% of the patients main-
tained weight loss. A reduction of both serum alanine
transaminase (ALT) and fasting insulin level correlated
with the amount of weight lost [26]. Similarly, Hickman
et al. reported weight loss was associated with a
decrease in serum liver enzymes, hepatic steatosis and
fibrosis score in obese patient with chronic hepatitis C
[27]. There are no studies as yet available assessing
whether these lifestyle interventions impact on response
to antiviral treatment.
Two recent studies have evaluated the effect of adding
an insulin sensitizer to the standard antiviral therapy
with mixed results. Overbeck and colleagues studied the
effects of pioglitazone in patients with hepatitis C who
previously failed standard therapy with ribavirin and
pegylated-interferon. However, none of the first five
patients included in the trial achieved a satisfactory viro-
logical response after 12 weeks of retreatment, despite
the fact that in at least three of them the insulin resis-
tance score improved. As a result, the study was termi-
nated early [28]. Others have suggested that this
combination might be beneficial in naïve patients with
chronic hepatitis C and insulin resistance. In a subse-
quent study, Romero-Gomez et al. evaluated the efficacy
of metformin in naïve, genotype 1 chronic hepatitis C
and insulin resistance patients in a multi-centered,
randomized, double-blinded, placebo-controlled trial.
Adding metformin to peginterferon and ribavirin was
safe and improved insulin sensitivity. Although the
study failed to show a statistically significant difference
between arms, it did show an improved sustained virolo-
gical response (SVR) in females [29].
Thus, larger, more definitive studies are still needed to
determine the potential utility of these interventions for
treatment of patients with chronic hepatitis C, insulin
resistance, and obesity.
At this point only lifestyle interventions can be recom-
mended to improve metabolic syndrome and obesity
associated with chronic hepatitis C, but their effect on
treatment response and long term outcome requires
further study.
Liver transplantation
Despite the various etiologies for end-stage liver disease
and subsequent liver transplantation, obesity has been
associated with post-transplant complications regardless
of the indication for transplant [30]. Post-transplant
adherence for liver recipients involves taking medica-
tions on a regular basis, keeping appointments, and
making and sustaining recommended lifestyle changes
related to smoking, drinking, drug use, and other high-
risk behaviors. With the majority of liver transplant reci-
pients surviving beyond the first year post-transplant,
the development of metabolic abnormalities contributes
significantly to morbidity and mortality in these patients
[31]. Several epidemiological studies have shown that
liver transplantation is associated with an increased pre-
valence of risk factors for cardiovascular disease, includ-
ing hypertension, diabetes mellitus, dyslipidemia, and
obesity, with reported rates of post-transplant metabolic
syndrome ranging from 43 to 58% [32-34]. The etiology
of these conditions is most likely multi-factorial includ-
ing changes in body habitus as well as side effects of
medications. In addition, diabetes has been shown to be
an independent risk factor for mortality following liver
transplantation [35]. This translates to an elevated cardi-
ovascular event rate in post-liver transplant patients
with metabolic syndrome. In a recent study it was
reported that after an average of 58 months of follow-up
in 118 post liver transplant patients, 30% of patients
with concomitant metabolic syndrome experienced
major cardiovascular events as compared with 8% of
patients without metabolic syndrome [32].
Thus, it is apparent that counseling regarding manage-
ment of obesity should be initiated for both patients
undergoing evaluation for liver transplant and liver
transplant recipients. Studies examining the long term
effects of lifestyle interventions for obesity and meta-
bolic syndrome in patients after liver transplantation
have yet to be published.
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One of the first steps for patients with obesity and
chronic liver disease is a therapeutic lifestyle change.
We know that obesity management not only contributes
to weight loss, but also enhances insulin sensitivity,
modifies the serum lipid profiles and contributes to
improved quality-of-life [9]. A recent study detailed the
differences in diet between lean, overweight and obese
subjects with NAFLD and hepatitis C [36]. This study
showed that patients in the higher BMI groups (that is,
BMI >25) consumed more high fat sources of protein,
foods with a high sodium content and higher fat milk
products. Another recent study has also shown the posi-
tive health effects of practical lifestyle intervention based
on behavior-change theory after three months on liver
enzymes and other metabolic risk factors [9]. This study
by St. George et al. was the first on the effects of a com-
prehensive lifestyle intervention as opposed to intense
weight loss alone in patients with liver disease. Using a
large sample size and a no-treatment control group, the
authors demonstrated that even small changes in weight
and even weight maintenance in conjunction with
improved dietary and physical activity can bring about
improvements in metabolic and liver test profiles of
these patients. This provides support for practitioners to
encourage patients with liver disease to undertake and
maintain positive lifestyle changes irrespective of
whether large weight loss occurs.
We and others have demonstrated in a research set-
ting that sustained weight loss of even a few kilograms
has a beneficial effect on the biochemical and histologi-
cal features of disease in overweight patients with
NAFLD and chronic HCV [8,16]. In one of the only
randomized, controlled trials examining the effects of
weight loss on NAFLD after intensive lifestyle modifica-
tion, it was reported that after 48 weeks of intervention,
patients who received intensive lifestyle modification
lost 9.3% of their body weight as compared to 0.2% loss
in control subjects [37]. Impo r t a n t l y ,i na d d i t i o nt o
weight loss, patients experienced improvement in the
NAS activity score as well as reduction in alanine trans-
aminase levels. These studies reflect the need for effec-
tive methods of weight reduction in an outpatient
setting to become a more important aspect of clinical
care. Despite the recognized benefits, achieving even
modest amounts of weight loss and maintaining it in
clinical practice is difficult. Intensive interventions that
mimic those established by research projects are per-
ceived as expensive and demanding on the dietetic ser-
vice. Typically, patients are unable to lose or even
maintain their weight, so they lose motivation. In these
cases, the patients do not follow through with lifestyle
interventions and/or use pharmacological interventions
instead. Therefore, when discussing physical activity
with patients, the discussion should focus on impedi-
ments to increasing physical activity and finding ways
for patients to incorporate exercise into their lives on a
regular basis. It is often helpful to separate the benefits
of exercise from weight loss. Since exercise has its own
benefits in terms of a sense of well-being, and improved
metabolic status including insulin sensitivity and hepatic
steatosis. Being discouraged about lack of weight loss
during these lifestyle interventions should not be a
reason to quit.
Successful introduction of lifestyle interventions into
clinical practice requires facilitation and support from all
levels of staff within the liver clinic. Aspects of the service
structure that we believe are important to the success of
the program are an initial intensive period of weekly
review for 12 weeks followed by long-term support.
Components of a successful program also include the
commitment of a dietitian who has an interest in weight
management, a consulting room physically located within
the hepatology department, and support from medical
and nursing staff. For patients who are unable to demon-
strate long term weight loss and/or have continued liver
damage, specific combinations of drugs and diet therapies
may be tailored to target one or multiple metabolic path-
ways to regulate lipid metabolism and ultimately influ-
ence circulating plasma biomarkers of cardiovascular
disease. Furthermore, combined drug/diet approaches in
the change of lifestyle may reduce the number of drug
prescriptions, the progressive increase in ‘’optimal’’ drug
dosage, and costs associated with pharmaceutical disease
management.
Conclusions
Individuals with chronic liver disease have lower QOL
than the general population, with and without associated
chronic illness. A decline in physical health is particu-
larly apparent. When these conditions are present in
patients who are also overweight or obese, QOL declines
even further, along with an increased risk of other
potential medical and hepatic complications. As we have
discussed in detail in this review, lifestyle interventions
including healthy eating, exercise and controlled weight
loss have been shown to improve liver damage related
to hepatic steatosis and other complications of obesity
and the metabolic syndrome. Lifestyle changes should
be an important adjuvant to medical therapies for
patients with HCV infection, liver transplant status, and
NAFLD as well as other chronic hepatic conditions.
Interventions related to diet and exercises are also our
best first-line therapy for patients with hepatic steatosis
related to underlying obesity. Future research should
focus on identifying modifiable factors that affect QOL
and can be targeted for improvement. The independent
inverse relationship between chronic liver disease and
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tion between these entities warrants additional attention
as these patients will increasingly be co-managed by
internists, endocrinologists, and hepatologists.
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